TAURX-PHARMACEUTICALS
5.2.2024 09:01:29 CET | Business Wire | Press release
TauRx Pharmaceuticals Ltd., a global leader in Tau-based research in Alzheimer’s disease (AD), announced today that the company will present the 24-month data from its Phase III LUCIDITY trial of hydromethylthionine mesylate (HMTM) at the upcoming AD/PD™ 2024 Alzheimer's & Parkinson's Diseases Conference from 5-9 March 2024, in Lisbon, Portugal.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240205168572/en/
Professor Claude Wischik (Photo: Business Wire)
Professor Claude Wischik, Co-Founder, CEO and Executive Chairman of TauRx will present data including details of the final 12-month open label phase of the study indicating maintenance of subjects with mild cognitive impairment due to Alzheimer’s at baseline cognitive scores. A panel, moderated by Dr. Serge Gauthier and including Professor Henrik Zetterberg, Professor Alistair Burns, and Dr. David Watson, will discuss the relevancy of these data and the potential impact of HMTM on people living with Alzheimer’s.
“We believe that presentation and discussion of this data represents an important step in our mission to bring people living with Alzheimer’s and their loved ones a safe and effective oral treatment that they will be able to access,” said Professor Claude Wischik. “Alzheimer’s is a global problem, one that impacts millions of people in some way at some point, and we are determined to help those impacted by this disease.”
HMTM is designed for early intervention to modify the disease, slowing progression of AD. If approved, HMTM will be the first oral, anti-tau therapy with a robust safety profile requiring minimal testing and treatment monitoring. This simplified profile will promote accessibility and affordability for people living with Alzheimer’s.
At the conference, TauRx will present the data during a moderated panel discussion at 13:50 CET on 7 March (Abstract #2363; “24-month topline results from Phase III LUCIDITY trial in AD show combined disease-modifying and symptomatic activity for HMTM”) and host an additional question and answer session on 9 March. Professor Wischik will also participate in a forum discussion “Anti-tau therapies in clinical trials—what are the challenges and opportunities for a rational therapy?” on 8 March.
TauRx has initiated regulatory engagement in the UK and the US for intended product approval. Other territories will follow in line with plans to scale commercialisation of HMTM.
For additional information, please visit: https://taurx.com/ or https://adpd.kenes.com/.
TAU PATHOLOGY IN ALZHEIMER’S
Through dedicated research programs, it is understood that certain age-related factors lead to misfolding and aggregation of tau proteins, and the subsequent formation of tau tangles in Alzheimer’s. Pathological aggregation of tau protein disrupts and damages neuronal function. The process begins many years before symptoms of dementia are seen. Tau pathology has been proven to correlate with the clinical decline (loss of memory and ability to care for oneself) commonly seen in people with Alzheimer’s, establishing it as an important target for treatment. HMTM is primarily a tau aggregation inhibitor, which effectively crosses the blood brain barrier to target the source of this damaging process. Its secondary pharmacological action is symptomatic through increasing acetylcholine levels in parts of the brain essential for memory functions.
ABOUT LUCIDITY
Completed in June 2023, LUCIDITY was a double-blind randomised controlled Phase III clinical trial comparing change over 12 months in cognitive, functional and brain atrophy outcomes at HMTM doses of 16 mg/day, 8 mg/day and methylthioninium chloride (MTC) at a dose of 4 mg twice weekly as a control in a 4:1:4 randomisation, with a subsequent 12 month blinded open-label extension phase in which all participants received 16 mg/day.
ABOUT TAURx PHARMACEUTICALS LTD
TauRx was founded in 2002 in Singapore, with primary research facilities and operations based in Aberdeen, UK. The company has dedicated the past two decades to developing treatments and diagnostics for Alzheimer’s and other neurodegenerative diseases due to pathological aggregation of tau and other proteins.
Alzheimer’s disease is a leading cause of disability and death throughout the world and is one of the most important global public health issues. TauRx will contribute to addressing this unmet need with data from LUCIDITY and pursuit of regulatory approvals in line with its overall plans to make HMTM available for people living Alzheimer’s. Future research is planned for other related neurodegenerative diseases. https://taurx.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240205168572/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vultr, SUSE & Supermicro Debut Unified Cloud-to-Edge Architecture for Global AI Scaling6.5.2026 14:00:00 CEST | Press release
The strategic partnership bridges the gap between regional cloud and the far edge, combining ruggedized hardware and GitOps-driven Kubernetes to streamline large-scale AI deployments Vultr, the world's largest privately-held cloud infrastructure company, in collaboration with SUSE and Supermicro, today announces a strategic architectural framework designed to solve the complexities of deploying and operating AI workloads across distributed environments. As AI moves closer to the point of data creation - from manufacturing floors to retail storefronts - organizations face significant challenges in latency, cost and operational consistency. This joint initiative provides a seamless, Cloud-to-Edge pipeline that integrates high-performance hardware, localized cloud infrastructure, and unified Kubernetes management. The partnership addresses the reality that sending all data back to a central cloud is no longer viable for real-time AI. The solution breaks down the infrastructure into three
Waiv Enters Collaboration with Daiichi Sankyo to Deliver AI-Derived Biomarkers for ADC Program6.5.2026 14:00:00 CEST | Press release
Waiv, formerly Owkin Dx, to leverage its digital pathology platform encompassing foundation models and AI methodology for ADC biomarker discovery program Waiv, formerly Owkin Dx, a Paris-based company catalyzing AI precision testing, today announced it has entered a collaboration with Daiichi Sankyo (TSE: 4568) to lead digital pathology biomarker discovery for an antibody-drug conjugate (ADC) program. With deep expertise across diverse pathology and multimodal data, and a global data network spanning academic institutions, hospitals, and laboratories, Waiv has a proven track record delivering AI-powered biomarker solutions across the full drug development lifecycle. Under the collaboration, Waiv will apply its end-to-end computational pathology platform to early phase data. This includes tumor microenvironment (TME) analysis across both hematoxylin and eosin (H&E) and immunohistochemistry (IHC) stained samples, as well as biomarker discovery and outcome prediction capabilities aimed at
Elisa Expands PON Deployment with Vecima’s All-PON™ Shelf, Delivering 10G Fiber Services in Estonia6.5.2026 13:30:00 CEST | Press release
Elisa plans to install Vecima’s EXS1610 All-PON shelf across its footprint in Estonia, building on its existing Vecima PON deployment16-port EXS1610 All-PON Shelf supports a variety of PON standards, including GPON, XGS-PON, and 10G-EPON Vecima Networks Inc. (TSX: VCM) announced today that leading telecommunications operator Elisa has deployed Vecima’s Entra EXS1610 All-PON™ Shelf for 10G Fiber-to-the-Home (FTTH) services for its subscribers in Estonia. In Estonia’s competitive broadband market, Elisa brings highly innovative solutions to its subscribers. Vecima’s EXS1610 supports multiple deployment use cases, including greenfield, targeted brownfields, rural edge-outs, hybrid fiber-coax (HFC) overbuilds, footprint extensions, and hub collapses. Its compact shelf footprint can help reduce operating costs and allow operators to deploy anywhere – for maximum flexibility, including data centers, remote cabinets, the headend, and multi-dwelling units. The Entra EXS1610 All-PON Shelf featu
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany6.5.2026 13:01:00 CEST | Press release
-The agreement ensures sustainable access to this innovative therapy for eligible patients ages 12 years and older in Germany- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that a reimbursement agreement was signed with the GKV-Spitzenverband for its CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel). This agreement secures sustainable access to this innovative one-time treatment for eligible patients in Germany ages 12 years and older living with severe sickle cell disease or transfusion-dependent beta thalassemia. “For the first time in Germany, a long-term, sustainable access agreement to a gene therapy has been established for people living with sickle cell disease and transfusion-dependent beta thalassemia,” said Ludovic Fenaux, Senior Vice President, Vertex International. “This agreement represents significant progress for people living with these two devastating and life-shortening diseases. We are pleased to collaborate across the health c
Suzano Connects an Area the Size of Over 200,000 Soccer Fields Through Ecological Corridors in Just Four Years6.5.2026 13:00:00 CEST | Press release
Initiative integrates fragments of native forests in the Atlantic Forest, Cerrado and Amazon biomes, stimulating wildlife movement, the expansion of vegetation cover and the restoration of ecosystems Suzano, the world's largest pulp supplier, has connected 214,368 hectares of native forest in the Atlantic Forest, Cerrado, and Amazon biomes in Brazil by establishing ecological corridors, restoring an area larger than 200,000 soccer fields within four years. In 2025 alone, 55,366 hectares of native forest were connected, advancing Suzano’s public goal of connecting 500,000 hectares by 2030, as outlined in the Company’s recently published Sustainability Report. The implementation of ecological corridors is guided by decades of research and monitoring by Suzano and its partners. The aim is to connect larger fragments of land that host greater biodiversity, as well as those already monitored by experts, with sites where wildlife is limited or threatened. These corridors are designed to foll
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom